
Hemerion technology to be further evaluated in the DOSINDYGO multi-center clinical trial
The Hemerion technology, which associates drugs and photonic treatments against glioblastoma, is to be evaluated in the DOSINDYGO clinical trial.This new clinical trial is sponsored by CHU de Lille (PI Nicolas REYNS) and the Brussels Erasmus Hospital (PI Florence Lefranc) with the financial support of Fonds Erasme. Following the INDYGO trial which assessed the Hemerion …